While revenue growth and reduced losses are positive, the company remains deeply unprofitable and reliant on dilutive financing. Traders should monitor the upcoming Phase 2 interim data (possible catalyst in Q3) and watch for new capital raises. The narrow loss improvement was largely due to non-recurring 2024 charges — underlying fundamentals remain weak.
Price Chart
Executive Summary
Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, driven by higher sales and pricing, while gross profit remained flat at $223.8K. Net loss narrowed to $7.37M from $7.96M in 2024, primarily due to lower non-cash R&D charges, despite higher selling expenses. The company exhausted its $4M ATM shelf capacity and highlighted clinical progress in babesiosis, but continues to face going-concern uncertainty.
Key Financial Metrics
Key Facts
- FY2025 net product revenue increased 65% YoY to $1,005,000 from $607,600 in 2024
- Gross profit was $223.8K in 2025 vs. $222.8K in 2024, despite non-recurring inventory write-offs
- Operating expenses decreased to $8.4M from $10.0M in 2024, driven by $2.9M lower R&D costs (non-recurring charges in 2024)
- Net loss narrowed to $7.37M ($11.73/share) from $7.96M ($74.17/share) in 2024
- Company raised $4.03M via ATM, exhausting current shelf capacity
- 2.64M shares outstanding as of March 30, 2026
- All patients in expanded access study for relapsing babesiosis were cured with tafenoquine
- Interim data from Phase 2 B-FREE study expected as early as September 2026
- Partnerships with GoodRx and Runway Health expanded ARAKODA® distribution
- FDA approval risk, going-concern doubt, and lack of manufacturing capacity remain key risks
Financial Impact
Revenue up 65% to $1.005M; net loss improved by $590K; $4.03M in dilutive ATM financing
Risk Factors
- Substantial doubt about going-concern basis per forward-looking statements
- Heavy reliance on dilutive ATM financing; shelf capacity exhausted, next raise likely dilutive
- No manufacturing capacity, creating supply chain and timing risks
- Clinical trial outcomes uncertain; regulatory approval not guaranteed
- Revenue base still very small ($1M) despite 65% growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers